EditRx's EBT-101 targets latent HIV
- Excision BioTherapeutics’ EBT-101 is not a “shock and kill” HIV therapy. It is an in vivo CRISPR treatment built to cut latent HIV DNA out of cells. - In the first human Phase 1 study, 6 people enrolled and 3 stopped ART; all 3 had viral rebound, though safety looked acceptable. - That still matters because EBT-101 is among the first systemic CRISPR infectious-disease programs in humans — and delivery now looks like the real bottleneck.
EBT-101 is a gene-editing HIV treatment, but the basic framing around it often gets mangled. It is not a classic “shock and kill” drug that wakes up latent virus so the immune system can clear it. The whole idea is different — send CRISPR into the body, find HIV DNA that has been pasted into human cells, and cut out enough of that viral genome that the virus cannot come back. That is a much more direct cure strategy. It is also much harder than it sounds. ### What is EBT-101 actually trying to do? HIV’s real trick is latency. Even when antiretroviral therapy drives virus in the blood down to undetectable levels, copies of HIV remain stitched into the DNA of some long-lived cells. Stop the pills, and those hidden copies can start making virus again. EBT-101 is designed as a one-time intravenous CRISPR-Cas9 therapy that targets the integrated proviral genome itself, using multiple guide RNAs to cut HIV at more than one site. (clinicaltrials.gov) Basically, instead of suppressing HIV every day, it tries to physically disable the archived virus. ### Why isn’t that “shock and kill”? “Shock and kill” means two steps — first force latent HIV to reveal itself, then eliminate the newly visible infected cells. EBT-101 is better described as proviral excision or proviral targeting. The target is the latent viral DNA already sitting inside cells, not the latency program itself. That distinction matters because it changes what success depends on. A shock-and-kill drug needs strong reactivation and cleanup. EBT-101 needs the editor to reach enough infected cells across the body and cut accurately enough to matter. (clinicaltrials.gov) ### What happened in people? The first-in-human study, NCT05144386, enrolled 6 adults with HIV who were already aviremic on stable ART. It was an open-label, single-ascending-dose study, with a planned analytical treatment interruption after Week 12 for eligible participants. The trial record now lists the study as completed, with primary completion and study completion on November 14, 2024, and a 15-year long-term follow-up plan. (pmc.ncbi.nlm.nih.gov) ### Did it work? Not in the way people mean when they say “cure.” Early 2024 data showed EBT-101 met its primary safety endpoint and its biodistribution and immunogenicity endpoint. But among the first participants who paused ART, HIV came back. Three participants stopped antiretrovirals in the early dataset, and all three had viral rebound. Later conference coverage described rebound in four participants who entered treatment interruption. So the clean takeaway is simple — EBT-101 had encouraging safety, but it did not yet deliver durable ART-free control. (clinicaltrials.gov) ### So why are people still paying attention? Because this was one of the first systemic, in vivo CRISPR attempts against an infectious disease in humans. That is a big technical milestone even when the efficacy is weak. The trial showed you can give this kind of editor intravenously and not immediately run into catastrophic toxicity. For a field that has mostly talked about HIV cure in theory, that is real progress. But turns out the hard part was never just cutting DNA in a dish. (crisprmedicinenews.com) It is delivery — getting enough editor into enough reservoir cells in enough tissues. ### Why is delivery such a problem? Think of latent HIV reservoirs as a tiny number of infected cells scattered through a huge city. CRISPR does not help if the package reaches the right block but misses most of the apartments. Reviews of the field now make this point pretty bluntly: in vivo editing efficiency remains too low for strategies that need to hit essentially all intact proviruses. That is why newer delivery ideas — including lipid nanoparticles and combination approaches — keep coming up. (biospace.com) ### What’s the bottom line? EBT-101 is a real HIV cure experiment, but not the version circulating in some social posts. It does not “expose and remove” latent HIV in a shock-and-kill sense. It tries to cut latent HIV DNA directly — and the first human readout says the concept looks safer than many feared, but nowhere near potent enough yet to replace ART. That still makes it important. It tells the field where the wall actually is. (clinicaltrials.gov) (pmc.ncbi.nlm.nih.gov)
